⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVO News
Novo-Nordisk A/S
Heart Risks Go Beyond the Heart: Don’t Forget to Check Blood Sugar and Kidney Health
globenewswire.com
NVO
NVS
DVA
Novo Nordisk A/S - share repurchase programme
globenewswire.com
NVO
Remedy Meds GLP-1 Weight Loss 2026: Pricing, the FDA Compounding Shakeup, and What to Know Before You Commit to a Monthly Plan
accessnewswire.com
LLY
NVO
FDA approves Novo Nordisk's Awiqli®, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
prnewswire.com
NVO
Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
globenewswire.com
NVO
Resolutions from the Annual General Meeting of Novo Nordisk A/S
globenewswire.com
NVO
Kalohexis Announces Publication in Frontiers in Endocrinology Defining Design Criteria for Next-Generation Melanocortin Drugs for General Obesity
prnewswire.com
NVO
Novo Nordisk A/S: Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes
globenewswire.com
NVO
Lexaria's Oral GLP-1 Drug Strategy Validated by Industry
accessnewswire.com
LEXX
LLY
NVO
PFE
Accelerating GLP-1 Peptides to Market Through Integrated Formulation & Analytical Development, Upcoming Webinar Hosted by Xtalks
prnewswire.com
NVO
LLY